Literature DB >> 33093168

Tumor Fibroblast-Derived FGF2 Regulates Expression of SPRY1 in Esophageal Tumor-Infiltrating T Cells and Plays a Role in T-cell Exhaustion.

Qing-Yun Chen1, Yi-Ni Li2, Xin-Yue Wang1, Xu Zhang1, Yi Hu1, Lei Li1, Da-Qin Suo1, Ke Ni2, Zhuo Li1, Jia-Rong Zhan1, Ting-Ting Zeng1, Ying-Hui Zhu1, Yan Li1, Li-Jia Ma3, Xin-Yuan Guan4,5.   

Abstract

T-cell exhaustion was initially identified in chronic infection in mice and was subsequently described in humans with cancer. Although the distinct signature of exhausted T (TEX) cells in cancer has been well investigated, the molecular mechanism of T-cell exhaustion in cancer is not fully understood. Using single-cell RNA sequencing, we report here that TEX cells in esophageal cancer are more heterogeneous than previously clarified. Sprouty RTK signaling antagonist 1 (SPRY1) was notably enriched in two subsets of exhausted CD8+ T cells. When overexpressed, SPRY1 impaired T-cell activation by interacting with CBL, a negative regulator of ZAP-70 tyrosine phosphorylation. Data from the Tumor Immune Estimation Resource revealed a strong correlation between FGF2 and SPRY1 expression in esophageal cancer. High expression of FGF2 was evident in fibroblasts from esophageal cancer tissue and correlated with poor overall survival. In vitro administration of FGF2 significantly upregulated expression of SPRY1 in CD8+ T cells and attenuated T-cell receptor-triggered CD8+ T-cell activation. A mouse tumor model confirmed that overexpression of FGF2 in fibroblasts significantly upregulated SPRY1 expression in TEX cells, impaired T-cell cytotoxic activity, and promoted tumor growth. Thus, these findings identify FGF2 as an important regulator of SPRY1 expression involved in establishing the dysfunctional state of CD8+ T cells in esophageal cancer. SIGNIFICANCE: These findings reveal FGF2 as an important regulator of SPRY1 expression involved in establishing the dysfunctional state of CD8+ T cells and suggest that inhibition of FGF2 has potential clinical value in ESCC. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/24/5583/F1.large.jpg. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33093168     DOI: 10.1158/0008-5472.CAN-20-1542

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.

Authors:  Ran Jing; Irene Scarfo; Mohamad Ali Najia; Edroaldo Lummertz da Rocha; Areum Han; Michael Sanborn; Trevor Bingham; Caroline Kubaczka; Deepak K Jha; Marcelo Falchetti; Thorsten M Schlaeger; Trista E North; Marcela V Maus; George Q Daley
Journal:  Cell Stem Cell       Date:  2022-08-04       Impact factor: 25.269

Review 2.  Applications and Achievements of Single-Cell Sequencing in Gastrointestinal Cancer.

Authors:  Zhenliang Xie; Jincheng Li; Pu Huang; Ye Zhang; Jingkuan Yang; Kangdong Liu; Yanan Jiang
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

Review 3.  Cancer Associated Fibroblasts - An Impediment to Effective Anti-Cancer T Cell Immunity.

Authors:  Lilian Koppensteiner; Layla Mathieson; Richard A O'Connor; Ahsan R Akram
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

Review 4.  The Emerging Role of Tissue-Resident Memory CD8+ T Lymphocytes in Human Digestive Tract Cancers.

Authors:  Xinyu Mei; Huan Li; Xinpeng Zhou; Min Cheng; Kele Cui
Journal:  Front Oncol       Date:  2022-01-14       Impact factor: 6.244

5.  Sprouty1 exerts a preventive effect on the initiation of psoriasis by inhibiting innate immune antimicrobial peptide cathelicidin and immunocytes.

Authors:  Yuan Zhou; Ping Wang; Xue-Yan Chen; Bing-Xi Yan; Lilla Landeck; Zhao-Yuan Wang; Fan Xu; Min Zheng; Xiao-Yong Man
Journal:  Cell Prolif       Date:  2022-06-18       Impact factor: 8.755

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.